also recently signed an agreement to acquire Vascore Medical, a China-based manufacturer and distributor of advanced interventional cardiology devices.
The acquisition of worldwide and exclusive licensing rights for these novel coating technologies marks another step towards the strategic expansion of MIVT
's portfolio of intellectual property, and our exploration of the unique properties and exceptional biocompatibility of Hydroxyapatite," said Alan Lindsay, CEO of MIVT
Alan Lindsay, CEO of MIVT
stated "As we progress through our R&D program, all preliminary test results continue to support our firm belief that the company's proprietary HAp ultra-thin coating exhibits properties that provide our technology with a clear competitive advantage.
is significantly undervalued and we reaffirm our "speculative buy" rating and 12-18 month target price of $2.
President and CEO, Alan Lindsay said, "The critical path of our R&D program has passed another essential milestone.
Costa commented, "The preliminary nine month data of the MIVT
Pilot Trial are very encouraging, and reaffirm our positive findings at four months.
is developing a next-generation cardiovascular stent technology being designed to provide substantial health and safety benefits and outcomes over previous generations of drug-eluting stents.
also recently announced a breakthrough clinical trial marking the first time that the Company's proprietary hydroxyapatite coated stents has been implanted into a human patient.
Pilot Trial will evaluate the safety and efficacy of MIVT
's polymer-free nanoscale microporous hydroxyapatite drug-eluting stent for the treatment of single de novo lesions in native coronary arteries.
We feel confident that partnering with QUILT will provide MIVT
with the best possible business development resources as we bring product to the European marketplace," said Dr.
has acquired two major subsidiaries, including Biosync Scientific in India and SagaX in Israel to significantly expand product offerings, as well as design, manufacturing and distribution capabilities.
We are very pleased to announce that MIVT
is generating revenues for the first time in our Company's history," said Mark Landy, President of MIV Therapeutics.